LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology firm targeted on short-acting psychedelic-assisted therapies for psychological well being circumstances, broadcasts that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will take part in upcoming investor conferences this September.
Details of the classes are as follows:
H.C. Wainwright 24th Annual Global Investment Conference
Format: Fireside chat (digital)
Date: September 12-14, 2022
Time: On-demand from 7:00 a.m. ET on Monday, September 12, 2022
Conference hyperlink: Webcast entry right here
Jefferies Innovation in Mental Health Summit, New York City
Format: Fireside chat (in particular person)
Date: September 22, 2022
Time: 8:30 a.m. ET
Conference hyperlink: TBA – please verify again right here for an replace subsequent week
To schedule a one-on-one assembly with Small Pharma’s administration crew, please contact your respective assigned convention consultant or [email protected].
The shows and archived webcasts can even be accessible in the ‘Events and Conferences’ part of Small Pharma’s web site following the conferences
About Small Pharma
Small Pharma is a biotechnology firm progressing a pipeline of short-acting psychedelics with remedy for the remedy of psychological well being circumstances, with a present concentrate on melancholy. Small Pharma initiated a scientific program into N, N-dimethyltryptamine (“DMT”) assisted psychotherapy in February 2021. This program features a Phase I/IIa trial on the Company’s lead candidate alongside the event of a pipeline of proprietary preclinical belongings.
About DMT
DMT is a naturally occurring psychedelic tryptamine discovered in crops and in the mind of mammals. Scientific proof suggests DMT provides the potential for rapid-acting and long-lasting antidepressant results. DMT is differentiated by its quick psychedelic expertise (< 30 minutes), which permits for brief remedy classes and provides the potential for handy supervised therapies inside affected person clinics.
For additional data contact:
Small Pharma Inc.
George Tziras, Chief Executive Officer
Email: [email protected]
Tel: +1 (646) 751-4363
Investor Relations Contacts:
Eric Ribner
LifeSci Advisors
Email: [email protected]
Tel: +1 (646) 889-1200
Kristi Papanikolaw
KCSA Strategic Communications
Email: [email protected]
Tel: +1 (347) 487-6181
Media Relations Contacts:
USA – McKenna Miller
KCSA Strategic Communications
Email: [email protected]
Tel: +1 (949) 949-6585
Rest of World – Jaber Mohamed
MHP Communications
Email: [email protected]
Tel: +44 (0)7720 326 847
Cautionary Note
Small Pharma makes no medical, remedy or well being profit claims about its proposed merchandise. The U.Ok. Medicines and Healthcare merchandise Regulatory Agency (“MHRA”) or different comparable regulatory authorities haven’t evaluated claims concerning DMT-assisted therapies and different subsequent technology psychoactive compounds. The efficacy of such therapies has not been confirmed by MHRA-approved analysis. There is not any assurance that such DMT-assisted therapies and different psychoactive compounds can diagnose, deal with, remedy or stop any illness or situation. Vigorous scientific analysis and scientific trials are wanted. Any references to high quality, consistency, efficacy and security of potential therapies don’t suggest that Small Pharma verified such in scientific trials or that Small Pharma will full such trials. If Small Pharma can’t acquire the approvals or analysis obligatory to commercialize its business, it could have a cloth adversarial impact on Small Pharma’s efficiency and operations.
The TSX Venture Exchange (the “TSXV”) has neither authorised nor disapproved the contents of this information launch. Neither the TSXV nor its Regulation Services Provider (as that time period is outlined in the insurance policies of the TSXV) accepts accountability for the adequacy or accuracy of this launch.